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Total cholesterol to high density lipoprotein cholesterol ratio (TC/HDL) is an important 
prognostic factor for cardiovascular disease (CVD). This study used restricted cubic spline 
modelling to investigate the dose-response associations between TC/HDL and both CVD 
hospitalisation and CVD re-hospitalisation in two independent prospective cohorts. The 
East Cambridgeshire and Fenland (ECF) cohort includes 4,704 patients with type 2 
diabetes from 18 general practices in Cambridgeshire. The RAndomised controlled trial of 
Peer Support In type 2 Diabetes (RAPSID) cohort comprises 1,121 patients with type 2 
diabetes with post-trial follow-up data. TC/HDL and other demographic and clinical 
measurements were measured at baseline.  Outcomes were CVD hospitalisation over 2 
years, and CVD re-hospitalisation after 90 days of the prior CVD hospitalisation.   
Modelling showed nonlinear relationships between TC/HDL and risks of CVD 
hospitalisation and re-hospitalisation consistently in both cohorts (all P < 0.001 for linear 
tests). The lowest risks of CVD hospitalisation and re-hospitalisation were consistently 
found for TC/HDL at 2.8 (95% confidence interval: 2.6 to 3.0) in both cohorts and both 
overall and by gender. This is lower than the current lipid control target, 4.0 of TC/HDL.  
Reducing the TC/HDL target to 2.8 would include a further 33-44% patients with TC/HDL in 
the 2.8-4.0 range.  Studies are required to assess the effectiveness and cost effectiveness 
of the earlier introduction of, and more intensive, lipid lowering treatment needed to 
achieve this new lower TC/HDL target. 
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The prevalence and cost of diabetes is growing rapidly worldwide (1). People with 
diabetes are twice as likely to be admitted to hospital, and at least 10% of those in hospital 
have diabetes at any one time (2). In some locations and age groups, it is as many as one 
in five (3). The associated costs of excess admissions, as well as increased costs per 
admission, are significant contributors to the financial burden borne by healthcare 
systems from diabetes and often reflect preventable morbidity suffered by patients (4).  
As one of the most dominant risk factors, dyslipidaemia has been found to be associated 
with coronary heart disease (CHD) among people with type 2 diabetes in large 
prospective studies such as the UK Prospective Diabetes Study (UKPDS) (1, 2). Both total 
and low density lipoprotein (LDL) cholesterol have been found to correlate with risk of 
CHD consistently over different studies (5). Among various lipid profile measurements, 
the total cholesterol to high density lipoprotein cholesterol ratio (TC/HDL) has been 
widely used as a prognostic factor to predict the risk of CVD both in general  (3) and 
diabetes populations, as applied in the UKPDS score reflecting its association both with 
CHD (6) and stroke in people with type 2 diabetes. 
CVD hospitalisation and re-hospitalisation are important components of the increased 
costs of diabetes and the preventable morbidity suffered by people with diabetes (6). 
The TC/HDL management target among those with diabetes is an important risk factor 
for CVD hospitalisation and re-hospitalisation and might be useful in defining population 
risk of morbidity and increased health costs (7). Few studies have set out to investigate 
the associations between TC/HDL level and risk of CVD hospitalisation and re-
hospitalisation in people with type 2 diabetes. 
 
 












In our previous risk score to predict CVD hospitalisation and re-hospitalisation, TC and 
HDL were incorporated as 4 separated polynomial fractional terms to achieve a better 
model discrimination and calibration, which did not allow further examination of the 
association between the TC/HDL ratio and the risks of CVD hospitalisation and re-
hospitalisation (8).   For example, it is unclear whether or not there is a dose-response 
relationship between TC/HDL and the risk of hospitalisation in people with type 2 diabetes 
and if so, whether this is linear. If there is a non-linear relationship, and a potential 
threshold exists between TC/HDL and CVD hospitalisation, it could inform lipid 
management among people with type 2 diabetes in the primary care setting and thereby 
reducing hospitalisation and health payments. 
The aim of this study was to investigate the dose-response relationships between TC/HDL 
and risks of CVD hospitalisation over the subsequent 2 years, and CVD re-hospitalisation 




Data source and study population 
 
East Cambridgeshire and Fenland  cohort 
 
In the East Cambridgeshire and Fenland (ECF) cohort patient lists from 18 general 
practices across Cambridgeshire, England, in 2008/2009 were collated and linked with 
hospital admissions (Secondary Uses Service (SUS)) data as part of an evaluation of 
diabetes care across the county by the local health board, National Health Service (NHS) 
Cambridgeshire. This cohort was limited to volunteer practices using the Egton Medical 
Information Systems (EMIS) general practitioner (GP) software system, from which a 
predefined set of data could be extracted. There was no systematic selection process for 











these surgeries, and data extracted were for their entire diabetes population. Type 2 
diabetes was defined based on GP diagnosis (9). All patients with diabetes had follow-up 
hospitalisation data to 2010–2011. Hospital admissions to NHS and private hospitals within 
and outside Cambridgeshire were followed-up. No personal identifiers were released to 
researchers, and all subsequent analyses were conducted on anonymised datasets.  
RAndomised controlled trial of Peer Support In type 2 Diabetes cohort 
 
The design and methods of the RAndomised controlled trial of Peer Support In type 2 
Diabetes (RAPSID) trial have been published previously (7), as have its CONSORT 
(Consolidated Standards of Reporting Trials) diagram and the results of its primary 
outcomes (10).  Briefly, RAPSID was a 2x2 factorial cluster RCT comparing 4 groups: 
Controls, 1:1 (individual) peer support, group peer support, and combined 1:1 and group 
peer support among patients with type 2 diabetes. Participants had their diabetes for at 
least 12 months and those with dementia or psychotic illness were excluded.  Type 2 
diabetes was defined based on GP diagnosis. Participants were recruited from 
communities across Cambridgeshire and neighbouring areas of Essex and Hertfordshire.  
Follow up data were only available for participants in Cambridgeshire and neighbouring 
areas of Hertfordshire that are served by the Cambridgeshire and Peterborough Clinical 
Commissioning Group (CCG). Clusters were defined by local government (‘parish council’) 
boundaries.  The intervention was developed following a pilot (11), using a framework 
defined by Peers for Progress (12).  Peers facilitating peer support were termed peer 
support facilitators and their selection, training, support and the overall programme are 
described elsewhere (13). The intervention lasted 8-12 months and was commenced and 
concluded, cluster by cluster, between 02/06/11 to 12/04/12.  Ethics approval was received 
from the Cambridgeshire REC2 Committee (10/H0308/72), and signed consent included 
agreement for access to hospital data.   











At baseline, demographic data, blood pressure, and HbA1c and lipid profile were 
collected. Each participant was followed up until June 2015 (0.91-4.07 years follow-up 
from beginning/entry into the trial).  Hospitalisation (NHS hospitals & private hospitals), 
Accident & Emergency (A&E) and outpatient visits within/outside Cambridgeshire and the 
included areas of Hertfordshire were completely collected through Cambridgeshire and 
Peterborough Clinical CCG (14) including the elective/non-elective status, and International 
Classification of Diseases (ICD-10) codes (9).  
Defining CVD hospitalisation and re-hospitalisation 
The primary outcome of the study was having at least one hospitalisation with CVD as the 
primary diagnosis (ICD-10: I20–I25, I60–I69 and I73 in the first ICD field) over the 2-year 
follow-up and having at least one CVD re-hospitalisation after 90 days of prior CVD 
hospitalisation.  
Clinical measurements and missing data  
Objective clinical measurements were used as predictors in the model, including body 
mass index (BMI), blood pressure (systolic (SBP) and diastolic (DBP)) and the metabolic 
variables glycated haemoglobin (HbA1c) and lipid profile.  We also included demographic 
characteristics, (age and gender) and whether the patient was on lipid lowering 
treatment. Patients with diabetes were invited to have their blood pressure and 
metabolic variables measured at least once a year after the diagnosis of diabetes and the 
most recent was taken before 1 April 2009 (a minimum of 50 days before the first 
admission). Diabetes duration was not universally recorded, and hence was not usefully 
available for analysis. Diabetes therapy was not included in the dataset. The TC/HDL was 
defined as the ratio of total cholesterol to high density lipoprotein cholesterol. 
ECF cohort had missing information on body mass index (3.17%), systolic blood pressure 
(9.95%), diastolic blood pressure (9.95%), total cholesterol (12.35%), high density 











lipoprotein (14.56%), and low density lipoprotein (16.27%). We used multiple imputation to 
replace missing values by using a chained equation approach based on all candidate 
predictors and outcomes. We created 16 imputed datasets for missing variables that were 
then combined across all datasets by using Rubin’s rule to obtain final model estimates. 
Limited information was missing (<1%) in RAPSID and the complete dataset was used in 
our analysis. 
Ethical approval 
The derivation cohort work had approval from the Cambridgeshire research ethics 
committee as part of a wider service evaluation. Ethics approval for the validation cohort 
was received from the Cambridgeshire REC2 Committee (10/H0308/72), and signed 
consent included agreement for access to hospital data.   
Statistical analysis 
We used ‘incidence occurrence of CVD hospitalization after the first 90 days since the 
start of follow-up’, and the ‘incident occurrence of CVD re-hospitalisation’, as binary 
outcome measures. Multivariable logistic regression model was used to explore the 
prospective association between TC/HDL and risks of CVD hospitalisation and re-
hospitalisation with adjustment of co-variables presented in the Table-1. The adjusted 
incidence rates ratio was estimated as 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑	𝐼𝑅𝑅 = exp	(𝛽1), with estimated 
regression coefficients (β) from the multivariable logistic regression model. 
The dose-response relationships between TC/HDL and risks of CVD hospitalisation and re-
hospitalisation were estimated using a linear model, a natural cubic spline model with 
three equally spaced knots determined from the levels of TC/HDL measures, and a 
quadratic spline model. The natural cubic spline model was chosen as the best fit model 
for the relationship curve by its minimum Akaike information criterion (AIC) compared 
with the linear model or quadratic spline model. The linear test was used in the natural 











cubic spline model to test the linearity of the relationship. The break-point test11 was 
carried out to target the potential thresholds (P5 to P95 of TC/HDL measures) by 
incorporating the piecewise term into the cubic spline model. The threshold with a 
significant break in the regression coefficients and achieving the minimum AIC was 
chosen as the final threshold. The 95% CI of the threshold was obtained from 1000 
bootstrap samples. As the most important confounder, the role of the lipid lowering 
agents in the association between TC/HDL and risks of CVD hospitalisation and re-
hospitalisation was also presented. In the first sensitivity analyses, all analyses were 
carried out in the continuous measurement data-rich range (covering > 95% 





In the ECF cohort, we analysed information on 4,704 type 2 diabetes patients with 588 
CVD hospitalisations within 2 years and 316 re-hospitalisations after 90 days since a prior 
CVD hospitalisation. Our RAPSID cohort had information on 1,121 type 2 diabetes patients 
with 183 CVD hospitalisations and 78 re-hospitalisations. Table-1 summarises the basic 
characteristics and potential predictors of the study population at baseline. Patients with 
type 2 diabetes in both cohorts had similar age, gender, blood pressure and total 
cholesterol. Patients in the RAPSID cohort had a higher level of high density lipoprotein, 
low density lipoprotein, and HbA1c. Compared with the ECF cohort, those in the RAPSID 
cohort were more likely to be prescribed lipid lowering medicine and had more CVD 
hospitalisation and re-hospitalisation.  
Dose-response relationships between TC/HDL and CVD hospitalisation and re-
hospitalisation 











In both the ECF and RAPSID cohorts, non-linear (“J-shape”) relationships were found 
between TC/HDL and risks of CVD hospitalisation (both P-values for linearity test < 0.0001) 
and re-hospitalisation (both P-values for linearity test < 0.0001).  Relationship curves were 
derived from the natural cubic spline models with adjustment of covariates in Figure 1. 
Similar dose-response relationships were revealed in the sensitivity analyses modelling 
the associations within the data rich range (5th percentile to 95th percentile of the 
above measurements) as shown as Supplemental Figure S1 for both the ECF and 
RAPSID cohorts. In another sensitivity analysis modelling the associations by 
gender, similar dose-response relationships were identified in men and women for both 
the ECF and RAPSID cohorts (Supplemental Figure S2). 
 
For both CVD hospitalisation and re-hospitalisation, a TC/HDL below 2.8 (95% confidence 
interval: 2.6 to 3.0) was estimated to be associated with the lowest risk of CVD 
hospitalisation and re-hospitalisation both in ECF and RAPSID cohorts, as tested by linear 
threshold models. The thresholds are the same among  men and women. Table 2 shows 
the CVD hospitalisation and rehospitalisation rates below and above the threshold.  In the 
ECF cohort, the CVD hospitalisation rates below and above the threshold were 9.8% (0f 
2,211 participants) and 14.9% (0f 2,493 participants) respectively and in the RAPSID cohort, 
14.5% (of 269 patients) and 16.9% (of 852 patients) respectively.  Similarly, CVD 
rehospitalisation rates below and above the threshold were 4.1% and 9.0% in the ECF 
cohort and 6.6% and 7.2% in the RAPSID cohort. Table 2 also shows the risks of CVD 
hospitalisation and re-hospitalisation increase significantly with 1 unit increase of TC/HDL 
above the TC/HDL threshold (2.8) in both the ECF and RAPSID cohorts: adjusted incidence 
rates ratio (IRR) per TC/HDL unit for CVD hospitalisation 1.39 (95% CI: 1.37 to 1.41, P < 
0.0001) in ECF and 1.18 (1.15 to 1.22, P=0.012) in RAPSID; adjusted IRR for CVD 











rehospitalisation 1.20 (1.17 to 1.23, P < 0.0001) in ECF and 1.17 (1.13 to 1.21, P=0.040) in 
RAPSID. The risks of CVD hospitalisation and re-hospitalisation do not increase 
significantly with 1 unit increase of TC/HDL bellow the TC/HDL threshold (2.8) in either the 
ECF or RAPSID cohorts: adjusted IRR for CVD hospitalisation 1.05 (0.97 to 1.14, P=0.062) in 
ECF and 1.00 (0.85 to 1.19, P=0.595) in RAPSID; adjusted IRR for CVD rehospitalisation 1.04 
(0.94 to 1.17, P=0.272) in ECF and 0.90 (0.72 to 1.12, P=0.385) in RAPSID. Findings were 
similar in men and women (Supplemental Table S1). 
Lipid lowering agent was not a significant entrant into the model and the distribution of 
the TC/HDL ratio was not significantly different between patient with and without lipid 
lowering agent in each cohort (adjusted IRR for CVD hospitalisation: 1.01 (0.96 to 1.06) 
and 0.99 (0.89 to 1.09) for ECF and RAPSID cohorts, respectively; IRR for 
rehospitalisation: 0.99 (0.93 to 1.05) and 1.00 (0.98 to 1.01) for ECF and RAPSID cohorts, 
respectively). Similar findings were found in men and women: IRR for CVD hospitalisation: 
1.01 (0.90 to 1.14) and 1.01 (0.97 to 1.04) in men and 1.00 (0.99 to 1.01) and 0.99 (0.97 to 
1.02) in women for ECF and RAPSID cohorts, respectively; IRR for CVD rehospitalisation: 
1.00 (0.98 to 1.01) and 1.00 (0.96 to 1.05) in men and 1.00 (0.99 to 1.02) and 0.98 (0.94 to 
1.02) in women for ECF and RAPSID cohorts, respectively. 
DISCUSSSION 
Our study was undertaken to relate TC/HDL to the risks of CVD hospitalisation and re-
hospitalisation in two independent cohorts of patients with type 2 diabetes. We focused 
our investigation on the dose-response relationships assessing the evidence for non-
linear and particular in the existence of a threshold. In all our analyses, we found evidence 
that the associations are non-linear. Threshold analysis provided evidence of a TC/HDL 
threshold: 2.8 (2.6 to 3.0). The significantly higher risks of CVD admissions and re-
admissions were found above 2.8 of TC/HDL. 











Heart UK has recommended that a TC/HDL above 6 be regarded as a major risk factor for 
heart disease (15). However, Diabetes UK recommends a lower treatment goal of below 4 
in diabetes patients (16). There are some other studies which set the TC/HDL ratio target 
below 4 for patients with type 2 diabetes (17). However, based on our findings, 
comparing patients with TC/HDL at 2.8, for people with TC/HDL at 4.0, there was 55.2% 
and 24.0% increased risks of CVD hospitalisation within 2 years and re-hospitalisation after 
90 days of prior CVD hospitalisation, respectively.  
Our results extend previous findings, suggesting a `J-shaped’ non-linear association 
between TC/HDL and risks of both CVD hospitalisation and re-hospitalisation among 
people with type 2 diabetes. The existence of a non-linear relationship between TC/HDL 
and CVD outcomes has not been investigated before. In most previous studies, the 
association between TC/HDL and CVD outcomes were analysed by 1 unit or 1 standard 
deviation increase, assuming linearity (consistent slope), which may have led to an 
underestimate of the risk of CVD events (18,19). In other studies, the TC/HDL has been 
categorized into several groups based on percentiles, with the association analysed by 
increases by 1 unit or 1 standard deviation. The different slopes of association between 
TC/HDL and CVD outcomes have been presented over categories of TC/HDL, which also 
actually indicated the association was non-linear (20,21). However, a threshold could not 
be identified by this strategy. Moreover, this strategy of categorized exposure is not 
recommended, as it leads to the loss of statistical power and the introduction of residual 
confounders. Therefore, in our study, TC/HDL was treated as a continuous variable and 
non-linear models were examined in an independent cohort study as the best fitted 
model.  The  TC/HDL threshold of 2.8 of was consistently identified in both cohorts for 
both genders, and for both CVD  hospitalisation and re-hospitalisation.  











Previous studies have not focussed on CVD as both a major cause and cost for hospital 
admission among patients with diabetes. To understand the potential risk of CVD 
hospitalisation in the next year, and the risk of a new episode (within 90 days) of a CVD 
event (re-hospitalisation) could be helpful for clinicians to facilitate tailored, more 
intensive management to those with high TC/HDL and to reduce hospitalisation inpatient 
costs. 
Our study has several advantages. We examined associations between TC/HDL and CVD 
hospitalisation and re-hospitalisation in two independent prospective cohorts, which 
suggests the findings in this study are reliable. The variables used in this study are from 
routinely recorded demographic and clinical measurements in primary care settings, 
which suggesting that the findings in this study could increase the introduction of lipid 
lowering treatment for people with type 2 diabetes in clinical practice within countries 
that have routine recorded data accessible. We acknowledge that our study does not 
take into account diabetes duration, anti-diabetes treatments, prior history of CVD, other 
diabetes complications (e.g. renal failure), lifestyle risk factors (like smoking), and other 
comorbidities due to limitations in the original data due to limitations in the original data, 
but we feel that the clinical measurements included in our study could be proxies for 
missing predictors. A small minority of CVD events would have resulted in death, but data 
relating to mortality were not accessible due to linkage limitations. Based on the current 
study, the threshold is the same for the men and women. In this study, the event 
numbers are not enough for us to repeat the analyses by gender, which will be tested in 
the future studies. 
As far as we are aware, our study is the first study to investigate the associations 
between TC/HDL and the 2-year risk of CVD hospitalisation and re-hospitalisation within 
90 days of a previous hospitalisation in two independent prospective cohort studies. Our 











study has two important implications for clinical practice. First, the relationship between 
TC/HDL and CVD outcomes are non-linear, which suggests that the risk of CVD outcomes 
might be substantially under-estimated by previous studies in which linear shapes were 
assumed. Secondly, our finding suggests that type 2 diabetes patients with a TC/HDL ratio 
at 2.8 have the lowest risk of CVD outcomes: much lower than the 4.0, accepted in 
previous clinical guidelines.  This suggests that 33% (ECF cohort) - 44% (RAPSID cohort) of 
patients whose TC/HDL are between 2.8-4.0 (similar by gender: 32 (ECF) - 45% (RAPSID) in 
men; 34 (ECF) - 46% (RAPSID) in women) may need more intensive lipid lowering 
treatment, introduced at an earlier stage, to achieve this new optimal control target. 
Studies are required to assess the effectiveness and cost effectiveness of these 
strategies.   
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FIGURE LEGENDS AND TABLES 
 
Table-1. Baseline Characteristics of study populations in East Cambridge and Fenland 
(ECF) and RAPSID RAndomised controlled trial of Peer Support In type 2 Diabetes 
(RAPSID) cohorts 
  ECF cohort RAPSID cohort 
N 4,704 1,121 
Cardiovascular disease hospitalisation, n (%) 588 (12.5) 183 (16.3) 
Cardiovascular disease rehospitalisation, n (%) 316 (6.7) 78 (7.0) 
Female, n (%) 1,919 (40.8) 444 (39.6) 
Lipid Lowering treatment, n (%) 3,342 (71.4) 731 (65.2) 
Age, years 65.0 (56.o to 77.0) 65.8 (60.0 to 72.1) 
Body mass index, kg/m2 30.8 (26.2 to 34.3) 32.3 (28.0 to 35.4) 
Systolic blood pressure, mmHg 135.0 (125.0 to 143.0) 139.3 (128.3 to 151.0) 
Diastolic blood pressure, mmHg 76.5 (70.0 to 82.0) 75.5 (69.0 to 82.3) 
HbA1c, mmol/mol 61.6 (49.7 to 70.5) 56.5 (48.0 to 63.0) 
Total cholesterol, mmol/L 4.3 (3.6 to 5.0) 4.2 (3.6 to 5.0) 
High density lipoprotein, mmol/L 1.3 (1.0 to 1.6) 1.2 (1.0 to 1.4) 
Low density lipoprotein, mmol/L 2.5 (1.7 to 3.3) 2.4 (1.5 to 2.7) 
Total cholesterol to high density lipoprotein cholesterol ratio (TC/HDL) 3.1 (2.6 to 4.5) 3.7 (2.8 to 4.4) 























Table-2. Adjusted incidence rates ratios for cardiovascular disease (CVD) hospitalisation 
and re-hospitalisation by 1 unit increase in TC/HDL ratio in groups classified by TC/HDL 
threshold (2.8) in East Cambridge and Fenland (ECF) and RAPSID RAndomised controlled 
trial of Peer Support In type 2 Diabetes (RAPSID) cohorts 
 ‡ Indicates age and gender were adjusted; * indicates Age, gender, systolic blood pressure, diastolic 
blood pressure, body mass index, HbA1c, low density lipoprotein cholesterol, and lipid lowering 
treatment were adjusted. 
  
ECF Cohort RAPSID Cohort 
TC/HDL ratio ≤ 2.8 
P-
value 
TC/HDL ratio > 
2.8 
P-value 
TC/HDL ratio ≤ 
2.8 P-
value 
TC/HDL ratio > 
2.8 P-
value 
(n=2,211, (47.0%)) (n=2,493, (53.0%)) (n=269, (24.0%)) (n=852, (76.0%)) 
  CVD Hospitalisation 
Hospitalisation, n (%) 216 (9.8) -  372 (14.9) -  39 (14.5)   144 (16.9)   
Adjusted incidence rates 
ratio‡ 1.09 (1.00 to 1.19) 0.020  1.55 (1.53 to 1.57) 
 <0.000
1 
1.05 (0.86 to 
1.27)  0.890 1.24 (1.20 to 1.27) 0.016  
Adjusted incidence rates 
ratio* 1.05 (0.97 to 1.14)  0.062 1.39 (1.37 to 1.41) 
 <0.000
1 1.00 (0.85 to 1.19)  0.595 1.18 (1.15 to 1.22)  0.012 
  CVD Re-hospitalisation 
Re-hospitalisation, n (%) 91 (4.1)  - 225 (9.0) -  18 (6.6)   60 (7.2)   
Adjusted incidence rates 
ratio‡ 1.08 (0.95 to 1.22) 0.390 1.46 (1.43 to 1.49) 
<0.0001 1.07 (0.98 to 1.18) 0.932 1.30 (1.24 to 1.36) 0.001 
Adjusted incidence rates 
ratio* 1.04 (0.94 to 1.17) 0.272 1.20 (1.17 to 1.23) 




























Figure-1. Adjusted dose-response associations between total cholesterol to high density 
lipoprotein cholesterol ratio and adjusted odds ratios for cardiovascular disease (CVD) 
hospitalisation and rehospitalisation in East Cambridge and Fenland (ECF) and RAPSID 
RAndomised controlled trial of Peer Support In type 2 Diabetes (RAPSID) cohorts 
Age, gender, systolic blood pressure, diastolic blood pressure, body mass index, HbA1c, low density 
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